Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 102 participants.

Also called NCT05949281

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 102 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05949281
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05949281. Randomized; double masking; primary purpose treatment. Start 2023-08-29 (actual); primary completion 2031-01-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes
Acronym
REC1TE
Condition
Type 1 Diabetes
Condition
Cardiovascular Diseases
Condition
Chronic Inflammation
Intervention (Drug)
Colchicine 0.5 MG Oral Tablet
Intervention (Drug)
Placebo
Lead sponsor
Asger Lund, MD (class: other)
Collaborator
University of Copenhagen (class: other)
Collaborator
Juvenile Diabetes Research Foundation (class: other)

Record details

Record id
cardio:ct-nct05949281
Content hash
8dd24a67003caa708a5f6596441dbf1af4c29bede190b4ae0fb2e91d530e715a